Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2025)

Caris Life Sciences has reported Liabilities and Shareholders Equity over the past 2 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $1.1 billion for Q4 2025, up 227.48% from a year ago — trailing twelve months through Dec 2025 was $3.4 billion (changed N/A YoY), and the annual figure for FY2025 was $1.1 billion, up 227.48%.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.1 billion at Caris Life Sciences, up from $984.6 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CAI hit a ceiling of $1.1 billion in Q4 2025 and a floor of $343.7 million in Q4 2024.